<DOC>
	<DOCNO>NCT00023647</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Infusing vaccine directly lymph node may cause strong immune response kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy give directly lymph node treat patient stage IV melanoma .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Stage IV Melanoma</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety tolerability intranodal Synchrotope TA2M plasmid DNA vaccine patient stage IV melanoma . II . Determine immune response patient treat vaccine . III . Determine clinical response patient treat vaccine . OUTLINE : This dose-escalation , multicenter study . Patients receive Synchrotope TA2M plasmid DNA vaccine intranodally continuously 96 hour begin day 0 , 14 , 28 , 42 . Treatment continue 2 course absence disease progression unacceptable toxicity . Cohorts 8 patient receive escalate dos Synchrotope TA2M plasmid DNA vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose 2 8 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : Approximately 16-24 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>INCLUSION CRITERIA Patient must meet follow screen baseline visit : 1 . The patient legally acceptable representative must give sign informed consent participation study study procedure perform . 2 . Patients must 18 year age old prestudy 3 . Patients must ambulatory , ECOG performance status 0 1 ( Appendix II ) 4 . Patients histologically confirm diagnosis Stage IV melanoma accord AJCC/UICC modify system expect survival time 3 month 5 . Patients must positive HLAA2 ( Patients test positive within 5 year prestudy screen need test HLAA2 ) 6 . Patients must agree use acceptable method birth control 1. intrauterine device 2. oral hormonal contraception 3. combination spermicide barrier method 4. abstinence 7 . Female patient childbearing potential must confirm negative urine pregnancy test Day 0 EXCLUSION CRITERIA Patients meeting follow criterion NOT eligible study : 1 . Patients hematological abnormality evidence : 1 . Neutrophils &lt; 1,500/mm3 2 . Leukocytes &lt; 3,000/mm3 3 . Platelets &lt; 75,000/mm3 4 . Hemoglobin &lt; 9.0 g/dL 2 . Patients hepatic disease evidence : 1 . SGOT/SGPT ( AST/ALT ) &gt; 2.5 x upper limit normal ( ULN ) 2. alkaline phosphatase &gt; 2.5 x ULN 3 . Bilirubin &gt; 1.5 x ULN\ 4. positive hepatitis B surface antigen 5. positive hepatitis C antibody 3 . Patients know suspected renal impairment evidence : 1. serum creatinine &gt; 1.5 x ULN , and/or 2. serum urea &gt; 2.6 x ULN 4 . Patients history ocular melanoma 5 . Patients brain metastasis , unless complete resect 6 . Patients positive HIV antibody test 7 . Patients medical , sociological , psychological impediment may compromise compliance protocol 8 . Patients nurse , pregnant planning become pregnant within 6 month treatment completion 9 . Patients receive chemo , radio immunotherapy concurrently within precede four week 10 . Patients take drug affect immune function systemic corticosteroid immunomodulatory drug concurrently within precede four week 11 . Patients receive investigational drug concurrently within precede four week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>